Treatment

FDA issues warnings on illegal Alzheimer’s drugs

2880 1920 Peter Stevenson, PhD

On 11 February 2019, the United States Food and Drug Administration (FDA) issued warnings to 17 companies that illegally sold more than 50 products claiming to prevent, treat or cure…

read more

Stem-cell therapy puts the brakes on MS

2850 1900 Peter Stevenson, PhD

New data reveal the power of stem-cell transplantation in slowing or even halting disease progression in patients with RRMS, thereby reinvigorating further exploration of cellular treatments in MS. The findings…

read more

Cognitive impairment in MS

2048 1153 Mea Holm, PhD

Up to 70% of MS patients suffer from cognitive decline, which often has a profound impact on an individual’s quality of life. It is little surprise that MS researchers are…

read more

Results from the MS-SMART trial unveiled

3971 2975 Mea Holm, PhD

Secondary progressive multiple sclerosis (SPMS) is known to be extremely difficult to treat; there are no effective therapies for halting or reversing disability progression in the late disease phase. In…

read more

MS treatment strategy: Hitting hard and early, or minimising risks through stepwise escalation?

1969 1525 Mea Holm, PhD

With more than a dozen approved treatment options for relapsing-remitting multiple sclerosis (RRMS), treatment decision making is an increasingly complex task for neurologists. At ECTRIMS 2018, the topic on which…

read more

3 minutes with Prof. Goadsby – Interview from SNG

150 150 Rachel Park, MA

Professor Peter Sandor interviewed Professor Peter Goadsby at the SNG Annual Meeting this week in Montreux, Switzerland. They spoke about one of the top leading causes of disability–migraine. Watch the…

read more

Paralysis patients able to walk after epidural stimulation

3016 1900 Peter Stevenson, PhD

Patients with complete lower limb paralysis after spinal cord injury (SCI) have been given the ability to walk again, it was reported this week. In work published in Nature Medicine,…

read more

Quarterly migraine injection approved in US

2885 1900 Peter Stevenson, PhD

The US FDA has approved a new humanised monoclonal antibody for migraine prevention in adults. Fremanezumab-vfrm – under the brand name AJOVYTM (Teva Pharmaceuticals) – prevents the interaction between calcitonin…

read more

Gut feelings on MS: A conversation with Prof. Pot

2359 1740 Mea Holm, PhD

How does the gut–brain axis influence neuro-inflammation and the disease course of MS? Although we know that gut homeostasis and gut functions are closely related to food intake, we want…

read more

Sex hormones and their impact on migraines

2663 1800 Peter Stevenson, PhD

New understanding of the causation of migraines has led experts one step closer to identifying why females are 2–3 times more susceptible to migraines than males. A review from the…

read more
Brainwork is supported by unrestricted grants from: